PFE
31
-2
FOXA
62
3
HSIC
50
-7
XOM
60
-2
A
57
-5
DAL
76
2
NOV
45
-4
NTAP
46
-9
DHI
56
-2
GS
68
3
EQT
50
6
LYB
37
-4
LEN
41
-3
VIX
54
8
AFL
48
2
PEP
51
12
ALL
44
3
AAP
48
-2
KMI
48
6
CMG
54
-3
PFE
31
-2
FOXA
62
3
HSIC
50
-7
XOM
60
-2
A
57
-5
DAL
76
2
NOV
45
-4
NTAP
46
-9
DHI
56
-2
GS
68
3
EQT
50
6
LYB
37
-4
LEN
41
-3
VIX
54
8
AFL
48
2
PEP
51
12
ALL
44
3
AAP
48
-2
KMI
48
6
CMG
54
-3
Financhill
Back

Amphastar Pharmaceuticals 10K Form

Sell
27

AMPH
Amphastar Pharmaceuticals

Last Price:
$21.17
Seasonality Move:
-2.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AMPH News And Ratings

See the #1 stock for the next 7 days that we like better than AMPH

AMPH Financial Statistics

Sales & Book Value

Annual Sales: $732M
Cash Flow: $24.4M
Price / Cash Flow: 7.49
Annual Sales: $15.76
Price / Book: 1.38

Profitability

EPS (TTM): 2.76000
Net Income (TTM): $141.6M
Gross Margin: $373.9M
Return on Equity: 19.69%
Return on Assets: 9.06%

Amphastar Pharmaceuticals Earnings Forecast

Key Amphastar Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 22 years for AMPH is 51.08%.
  • The Selling, General & Administrative Expenses for AMPH have been equal to 12.91% of Gross Profit Margin.
  • The Research & Development expenses have been 10.10% of Revenue.
  • The Interest Expense is 19.02% of Operating Income.
  • The Net Earning history of AMPH is 21.79% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 11 years.

Amphastar Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AMPH
CUSIP: 03209R
Website: amphastar.com

Debt

Debt-to-Equity Ratio: 0.8
Current Ratio: 2.95
Quick Ratio: 1.92

Price-to-Earnings

Trailing P/E Ratio: 7.17
Forward P/E Ratio: 6.27

AMPH Technical Analysis vs Fundamental Analysis

Sell
27
Amphastar Pharmaceuticals (AMPH) is a Sell

Is Amphastar Pharmaceuticals a Buy or a Sell?